MHRA
- Local brand name: Omnitrope
- Status: approved
🇬🇧 Omnitrope in United Kingdom
NICE has issued 2 UK HTA decisions
Marketing authorisation
Health technology assessment
2 decisions from NICE for Omnitrope in United Kingdom.
NICE TA188 — — Decision pending classification
- Indication assessed: the treatment of growth failure in children
NICE made an unclassified decision on Omnitrope for the treatment of growth failure in children. The decision was based on the drug's effectiveness and cost. No Patient Access Scheme or commercial arrangement was considered.
NICE TA64 — ✓ Recommended
NICE recommended Omnitrope for a particular indication. However, the specific indication is not specified in the provided information. The decision was made without a reported ICER or a Patient Access Scheme.
Omnitrope in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United Kingdom
Frequently asked questions
Is Omnitrope approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Omnitrope in United Kingdom?
Serono is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Omnitrope been assessed by UK health technology agencies?
Yes — 2 UK HTA decisions on record from NICE.